Sun Pharmaceutical Industries INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$39Mgeneral payments (2019-2025)
$184Kresearch payments (2019-2025)
53,424clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Cequa $2.3M associated (2023-2025)
- Ilumya $2.2M associated (2023-2025)
- Winlevi $880K associated (2023-2025)
- Absorica Ld $655K associated (2023-2025)
- Odomzo $386K associated (2023-2025)
- Blu-U $231K associated (2023-2025)
- Yonsa $92K associated (2023-2025)
- Levulan Kerastick $86K associated (2023-2025)
- Xelpros $38K associated (2023-2025)
- Bromsite $19K associated (2023-2025)
- Leqselvi $9,807 associated (2023-2025)
- Sezaby $1,925 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| James Wharton | Lexington, KY | Dermatology | $866,140.18 |
| Steven Feldman | Winston Salem, NC | Dermatology | $676,657.78 |
| Leon Kircik | Lousiville, KY | Dermatology | $630,938.90 |
| Hilary Baldwin | Brooklyn, NY | Dermatology | $594,841.67 |
| Richard Adler | Baltimore, MD | Ophthalmology | $441,745.34 |
| Scott Gottlieb | Exton, PA | Dermatology | $413,904.04 |
| James Del Rosso | Las Vegas, NV | Mohs-Micrographic Surgery | $408,928.64 |
| Cory Rubin | Waterford, MI | Clinical & Laboratory Dermatological Immunology | $384,345.67 |
| Omar Noor | Somerset, NJ | $380,839.36 | |
| David Nelsen | Janesville, WI | Dermatology | $358,903.89 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.